I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Endometriosis is considered as a challenging disorder. Over 176 million women worldwide have been tormented by endometriosis associated pain and infertility, which severely affects their quality of life.\[[@ref1][@ref2]\] Unfortunately, there are still no specific markers and therapies. The essential reason for such adversity is due to the elusive pathogenesis. It is to date widely assumed that ectopic lesions arise through retrograde endometrial fragments during menstruation. Not all the women suffered endometriosis despite most women undergoing retrograde menstruation. The affected women may have certain susceptible factors, which partially comes down to the eutopic endometrium.\[[@ref3]\]

Evidences have indicated that gene expression level in eutopic endometrium of endometriosis is aberrantly altered by comparison with control endometrium.\[[@ref4][@ref5]\] These alterations of eutopic endometrium might be the source of the pathogenesis of endometriosis, which keep endometrial debris easier alive in the ectopic site. Recently, emerging evidences reveal that circular RNAs (circRNAs) are involved in regulating gene expression as competitive endogenous RNAs (ceRNAs).\[[@ref6][@ref7][@ref8]\] Moreover, circRNAs are characterized by covalently linked terminals and high stability as well as abundant expression level.\[[@ref9][@ref10]\] All abovementioned characteristics make circRNAs become evaluate indicators for diagnosis, prognosis, and therapeutic-response prediction. However, the relationship between circRNAs and endometriosis is unknown.

Given their pivotal biological roles, we investigated and identified dysregulated circRNAs in eutopic endometrium to offering new idea for diagnosis and treatment.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

This study was approved by the Institutional Review Board and Hospital Local Ethics Committee (No. JS-875). All participants provided informed consent.

Study population {#sec2-2}
----------------

A total of 63 clinical samples were collected at the Department of Obstetrics and Gynecology of Peking Union Medical College Hospital between May 1, 2016, and December 31, 2016. Eutopic endometrium samples were collected from 41 women who underwent hysteroscopic and laparoscopic surgery for ovarian endometriosis (22--46 years old; proliferative phase: *n* = 28; secretory phase: *n* = 13; American Fertility Society \[AFS\] Stage III--IV). Tissue samples of control endometrium were acquired from another 22 women without endometriosis who underwent hysteroscopy and laparoscopy for other benign ovarian cysts, infertility or uterine septum (no endometriosis, 25--43 years old; proliferative phase: *n* = 16; secretory phase: *n* = 6), similarly with a previous study.\[[@ref11]\] All patients met the criteria as follows: regular menstruation (25--32 days), no hormonotherapy for at least 6 months, and histopathology confirmation. All obtained samples were excluded from abnormalities of endometrium by the pathological diagnosis, and proliferative and secretory endometrium phases were distinguished by hematoxylin and eosin staining. Tissue collection and storage were conducted as described previously.\[[@ref12]\] Four samples for each group were randomly selected for a microarray analysis. Besides, all the samples were validated by quantitative real-time polymerase chain reaction (qRT-PCR).

Total RNA isolation and quality control {#sec2-3}
---------------------------------------

Total RNA was isolated with TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer\'s protocol. RNA quantity and quality were measured using a NanoDrop ND-1000 (Thermo Fisher Scientific, Wilmington, DE, USA). RNA integrity and genomic DNA contamination were assessed by denaturing agarose gel electrophoresis.

Circular RNA microarray analysis {#sec2-4}
--------------------------------

The Arraystar Human circRNA Array 8 × 15 K V2 Microarray (Arraystar, Rockville, MD, USA) contains 15,000 probes for 13,617 human circRNAs, all of which have been confirmed by Jeck *et al*.,\[[@ref10]\] Salzman *et al*.,\[[@ref13]\] Memczak *et al*.,\[[@ref14]\] Zhang *et al*.,\[[@ref15]\] Zhang *et al*.,\[[@ref16]\] Guo *et al*.,\[[@ref17]\] and You *et al*.\[[@ref18]\] Total RNA was first digested with Rnase R (Epicentre, Madison, WI, USA) to remove linear RNAs and enrich for circRNAs. Then, the enriched circRNA was amplified and transcribed into fluorescent complementary RNA, utilizing random primers according to the Arraystar Super RNA Labeling protocol (Arraystar). After hybridization and washing, processed slides were scanned using an Agilent Scanner G2505C (Agilent Technology, Santa Clara, CA, USA). Thereafter, Agilent Feature Extraction software (version 11.0.1.1, Agilent Technology, Santa Clara, CA, USA) was utilized to analyze acquired array images. Quantile normalization and subsequent data were processed using the R software package (version 3.3.1; R Foundation Inc. Vienna, Austria).

Quantitative real-time polymerase chain reaction validation {#sec2-5}
-----------------------------------------------------------

During the qRT-PCR validation stage, we recruited 41 endometria from patients with endometriosis and 22 normal endometria for control. Total isolated RNA was reversely transcribed using SuperScript III Reverse Transcriptase (Invitrogen Life Technologies). Subsequently, qRT-PCR was performed by ViiA 7 RT-PCR System (Applied Biosystems, Foster City, CA, USA) in a 10-μl reaction volume, including 5-μl 2 × PCR Master Mix (Arraystar), 0.5 μl/10 μmol/L forward/reverse primers, 2 μl cDNA, and 2 μl RNAase-free H~2~O. The cycling program was initiated from 95°C for 10 min, followed by 40 cycles of 95°C for 10 s and 60°C for 60 s. Divergent primers were designed and optimized for circRNAs. [Supplementary Table 1](#T1){ref-type="table"} listed all the PCR primers, the specificity of which was verified by a single-peak on the melting curve. The threshold cycle method (2^−ΔΔCT^) was used to calculate relative expression levels, which were normalized to β-actin levels.

###### 

Primers used for qRT-PCR

  Gene              Forward, 5'-3'            Reverse, 5'-3'
  ----------------- ------------------------- -------------------------
  β-actin           GTGGCCGAGGACTTTGATTG      CCTGTAACAACGCATCTCATATT
  circRNA_0004712   AGGGGTGAACCAGCCATTT       GCCAATCTCCCCTGAGTATGTT
  circRNA_0002198   GCAAACCTATATCAGGAAACAGC   TTGAAGAGGTGGCACAACAGT
  circRNA_0002503   CGTATTCACCTGCTCATCTCC     CTGGTGTTGGGATGATTTGA
  circRNA_0000141   TCAGGCCCCATGCAGGTG        ACCATGCCACTCGGATCCTC

qRT-PCR: Quantitative real-time polymerase chain reaction.

Bioinformatics analysis {#sec2-6}
-----------------------

To further elucidate the role of circRNAs in endometriosis, we first used the Arraystar target prediction software based on TargetScan\[[@ref19]\] and miRanda\[[@ref20]\] to predict the targeted miRNAs of each circRNA, which described interactions between circRNAs and miRNAs. According to the miRNA support vector regression (mirSVR) algorithm, we ranked the top five predicted miRNA targets for each circRNA. Then, we used TargetScan and miRDB to predict the related target genes according to the miRNAs targeted by circRNAs. Finally, the interaction network was depicted using the validated circRNAs and predicted miRNAs/mRNAs, preliminarily accounting for interactions of circRNAs-miRNAs-mRNAs in pathogenesis of endometriosis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses further annotated the function and signaling pathways of these genes.

Statistical analysis {#sec2-7}
--------------------

Data were first explored by the tests of normality. If the normal distribution was satisfied, Student\'s *t*-tests was used; otherwise, nonparametric Mann-Whitney *U*-test was used. The thresholds for differentially expressed circRNAs were expressed as an absolute value of fold change (FC) \>2 (EuE = 1) and *P* \< 0.05. Above statistical analyses were processed with R software version 3.3.1 and GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA).

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Clinical characteristics of the participants {#sec2-8}
--------------------------------------------

In the study, a total of 63 endometrial biopsies were obtained from women with laparoscopically and histopathologically proven presence (*n* = 41) or absence (*n* = 22) of endometriosis. The clinical characteristics of the participants were presented in Supplementary Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} where the mean (standard deviation) ages of patients in endometriosis and control group were 32 ± 6 years and 32 ± 5 years, respectively. There were no differences in age, cycle phase, parity, and infertility between two groups. Patients with endometriosis were more likely to gain moderate-to-severe dysmenorrhea (visual analogue scale \[VAS\] ≥4) and high level of CA125 by comparison with controls (*Z* = −2.627, *P* = 0.009 and *t* = 7.529, *P* \< 0.001, respectively). All the patients with endometriosis were judged to be Stage III and IV according to the AFS staging system.

###### 

Clinical characteristics of 41 patients with ovarian endometriosis

  Patient   Cycle phase     Age (years)   Parity   Infertility   VAS    CA125   Diameter of cyst (cm)   rAFS stage   Indication for surgery
  --------- --------------- ------------- -------- ------------- ------ ------- ----------------------- ------------ ------------------------
  1         Proliferative   31            0        Yes           6.5    44.1    3.8                     IV           Pain/infertility
  2         Proliferative   33            0        Yes           8.0    81.8    2.5                     IV           Pain/infertility
  3         Proliferative   28            0        N/A           7.5    34.6    5.8                     III          Pain
  4         Proliferative   33            0        N/A           6.5    34.1    4.8                     III          Pain
  5         Secretory       45            2        No            0      54.1    7.6                     IV           Cyst
  6         Secretory       28            0        N/A           0      56.6    6.7                     IV           Cyst
  7         Secretory       28            1        No            4.5    28.1    4.6                     III          Infertility
  8         Proliferative   33            2        No            5.5    46.9    4.7                     IV           Pain
  9         Secretory       30            0        N/A           4.0    30.1    4.9                     III          Pain
  10        Proliferative   30            0        Yes           5.0    24.2    5.8                     III          Pain/infertility
  11        Proliferative   45            1        No            4.5    108.8   5.9                     IV           Pain
  12        Secretory       29            0        Yes           4.5    79.0    3.8                     IV           Pain/infertility
  13        Secretory       29            2        No            4.5    63.2    5.9                     IV           Pain
  14        Proliferative   32            2        No            0      1.9     6.4                     III          Cyst
  15        Secretory       27            0        N/A           7.0    60.5    5.3                     IV           Pain
  16        Proliferative   30            0        Yes           3.5    52.1    3.4                     III          Pain/infertility
  17        Proliferative   32            2        No            2.0    70.7    5.1                     IV           Cyst
  18        Proliferative   37            5        No            3.0    51.6    4.2                     IV           Pain
  19        Proliferative   32            1        No            4.0    23.1    7.0                     III          Pain
  20        Proliferative   28            0        N/A           0      51.0    5.0                     IV           Cyst
  21        Proliferative   39            2        No            5.5    37.1    6.5                     III          Pain
  22        Secretory       38            1        No            6.0    76.4    2.9                     IV           Pain
  23        Proliferative   25            0        N/A           0      60.5    7.3                     IV           Cyst
  24        Proliferative   38            2        No            8.5    59.7    4.9                     IV           Pain
  25        Proliferative   24            0        N/A           4.0    40.3    6.7                     III          Pain
  26        Proliferative   25            0        N/A           7.5    30.2    5.9                     IV           Pain
  27        Proliferative   33            1        No            7.5    78.3    5.5                     IV           Pain
  28        Proliferative   30            0        N/A           0      37.4    5.3                     III          Cyst
  29        Secretory       25            0        N/A           2.0    42.0    8.3                     IV           Cyst
  30        Proliferative   34            3        No            0      185.2   6.6                     III          Cyst
  31        Secretory       36            0        Yes           0      29.3    4.5                     IV           Infertility
  32        Secretory       25            0        Yes           2.0    31.5    3.5                     III          Infertility
  33        Proliferative   31            0        N/A           5.5    56.6    4.8                     IV           Pain
  34        Proliferative   39            1        No            0      96.0    7.1                     IV           Cyst
  35        Secretory       46            1        No            0      22.4    3.6                     III          Cyst
  36        Proliferative   32            1        No            10.0   21.9    13.2                    IV           Pain
  37        Secretory       26            0        N/A           0      96.2    4.5                     IV           Cyst
  38        Proliferative   22            0        N/A           3.0    66.8    4.6                     III          Pain
  39        Proliferative   43            1        No            5.0    40.3    5.3                     IV           Pain
  40        Proliferative   29            0        N/A           5.0    24.4    7.0                     IV           Pain
  41        Proliferative   25            0        N/A           6.5    79.0    1.8                     III          Pain

N/A: Never attempted pregnancy; VAS: Visual analogue scale; rAFS: Revised American Fertility Society.

###### 

Clinical characteristics of 22 patients without ovarian endometriosis

  Patient   Cycle phase     Age (years)   Parity   Infertility   Pathologic diagnosis        VAS   CA125   Diameter of cyst (cm)   Indication for surgery
  --------- --------------- ------------- -------- ------------- --------------------------- ----- ------- ----------------------- ------------------------
  1         Proliferative   27            0        N/A           Teratoma                    0     14      4.9                     Cyst
  2         Proliferative   26            0        N/A           Serous cystadenoma          0     12.3    10.4                    Cyst
  3         Proliferative   30            1        No            Teratoma                    0     12.7    8.0                     Cyst
  4         Proliferative   27            0        Yes           Simple cyst                 3.0   13.7    3.1                     Cyst infertility
  5         Secretory       34            1        No            Secretory endometrium       2.5   15.2    --                      Uterine diverticula
  6         Proliferative   25            1        No            Proliferative endometrium   0     9.3     --                      Uterine septum
  7         Secretory       29            0        N/A           Teratoma                    0     14.3    4.6                     Cyst
  8         Secretory       32            0        N/A           Paraovarian cyst            3.5   18.8    6.8                     Cyst
  9         Proliferative   30            0        N/A           Teratoma                    6.5   20.4    5.0                     Cyst
  10        Proliferative   31            1        No            Proliferative endometrium   0     22.3    --                      Uterine septum
  11        Proliferative   34            1        No            Mesosalpinx cyst            0     18.6    6.7                     Cyst
  12        Proliferative   43            2        No            Simple cyst                 0     19.3    --                      Cyst
  13        Proliferative   32            0        N/A           Mesosalpinx cyst            4.5   20.2    4.0                     Cyst
  14        Secretory       39            5        No            Serous cystadenoma          3.5   17.7    6.4                     Cyst
  15        Proliferative   39            3        No            Teratoma                    6.5   8.5     4.0                     Cyst
  16        Secretory       26            0        N/A           Teratoma                    5.0   9.2     5.5                     Cyst
  17        Proliferative   37            6        No            Teratoma                    0     19.7    4.1                     Cyst
  18        Proliferative   36            5        No            Teratoma                    0     13.4    3.7                     Cyst
  19        Proliferative   33            2        No            Teratoma                    0     29.8    3.6                     Cyst
  20        Proliferative   31            0        N/A           Serous cystadenoma          0     17.2    5.1                     Cyst
  21        Secretory       25            0        N/A           Teratoma                    3.5   11.5    5.9                     Cyst
  22        Proliferative   34            2        No            Proliferative endometrium   3.5   8.7     --                      Uterine diverticula

N/A: Never attempted pregnancy; VAS: Visual analogue scale.

Circular RNA expression profiles in eutopic endometrium relative to those in normal endometrium {#sec2-9}
-----------------------------------------------------------------------------------------------

According to the circRNA microarray, a total of 88 circRNAs, 11 significantly upregulated and 77 significantly downregulated, were differentially expressed between eutopic endometrium and normal endometrium. The two types of endometrial tissue could be clearly distinguished using hierarchical clustering, scatterplot, and volcano plots \[[Figure 1](#F1){ref-type="fig"}\]. Hierarchical clustering indicated the relative expression level of circRNAs in eutopic and normal endometrium. Scatter plot evaluated the variation in circRNA expression between the two groups. Volcano plot displayed the statistical significance of differentially expressed circRNAs between cases and controls.

![circRNA expression patterns in eutopic endometrium (Group T) relative to those in normal endometrium (Group C). (a) Hierarchical clustering of circRNAs. Each group included four individuals. circRNAs are represented by single rows and samples by single columns. The color scale indicates relative expression, upregulation (red), and downregulation (green). Fold change \>2 and *P* \< 0.05 were regarded as the differentially expressed circRNAs. (b) Scatter plot of circRNAs. The values corresponding to the X- and Y-axes are the normalized signal values. (c) Volcano plot of circRNAs. The values on the X- and Y-axes represent normalized fold changes and *P* values, respectively. The red points represent significantly differentially expressed circRNAs. circRNAs: Circular RNA.](CMJ-131-559-g001){#F1}

Quantitative real-time polymerase chain reaction validation of selected circular RNAs {#sec2-10}
-------------------------------------------------------------------------------------

To confirm the differentially expressed circRNAs in the microarray, four circRNAs were selected for validation based on the following criteria: (1) upregulated in eutopic endometrium, (2) FCs \>2, (3) *P* \< 0.05, (4) raw intensity \>200, (5) exonic-related circRNAs, and (6) length between 200 and 3000 bp. Of them, two circRNAs (*circ_0004712* and *circ_0002198*) matched the microarray results and met the statistical cutoff by comparison with control endometrium \[*Z* = −2.653, *P* = 0.008; *Z* = −4.498, *P* \< 0.001; [Figure 2a](#F2){ref-type="fig"}\]. *circRNA_0002503* was expressed at a higher level in the eutopic endometrium of patients with endometriosis; however, the difference was not statistically significant. And, *circ_0000141* could not be amplified by qPCR % \[[Figure 2a](#F2){ref-type="fig"}\]. Intriguingly, the two validated circRNAs were not affected by the menstrual cycle \[[Figure 2b](#F2){ref-type="fig"}\]. We also performed a subgroup analysis between VAS and CA125, respectively, where patients with endometriosis were classified as two groups: one with moderate-to-severe dysmenorrhea (VAS ≥4) or CA125 \>35 U/ml and the other with VAS \<4 or CA125 ≤35 U/ml. As a result, no significant association between the two validated circRNAs and VAS or CA125 was found \[Supplementary Figure 1\]. Receiver operating characteristic curve analyses revealed that *circ_0004712* and *circ_0002198* were valuable biomarkers for distinguishing women with or without endometriosis, with area under curve (AUC) value of 0.704 (95% confidence interval \[*CI*\]: 0.571--0.837; *P* = 0.008) and 0.846 (95% *CI*: 0.752--0.939; *P* = 0.000), respectively \[[Figure 3](#F3){ref-type="fig"}\]. The diagnostic power of circ_0004712 achieved notable improvement when the *circ_0004712* and *circ_0002198* werecombined, while that of *circ_0002198* was not improved (AUC = 0.819; 95% *CI*: 0.713--0.925; *P* = 0.000).

![qRT-PCR validation of the four selected circRNAs. (a) The results of microarray and qPCR are shown as blue and red columns. Data that coincided with the microarray results and met the statistical cut-off are marked with \**P* \< 0.05 and ^†^*P* \< 0.001. (b) Effect of menstrual cycle on the two identified circRNAs. Data are expressed as fold changes relative to the values for the proliferative phase group of controls. Both the circRNAs show no significant changes between proliferative (red columns) and secretory phases (blue columns). qRT-PCR: Quantitative real-time polymerase chain reaction; qPCR: Quantitative polymerase chain reaction; circRNAs: Circular RNAs.](CMJ-131-559-g002){#F2}

###### 

The association between the two validated circRNAs and VAS or CA125. (a) The association between *circ_0002198* and VAS or CA125.(b) The association between *circ_0004712* and VAS or CA125. VAS: Visual analogue scale.

###### 

Click here for additional data file.

![The receiver operating characteristic curve of specific circRNAs in distinguishing endometriosis. *circ_0004712* and *circ_0002198* were valuable biomarkers for distinguishing endometriosis, with AUC value of 0.704 (95% *CI*: 0.571--0.837; *P* = 0.008) and 0.846 (95% *CI*: 0.752--0.939; *P* \< 0.001), respectively. The diagnostic power of circ_0004712 achieved notable improvement when the *circ_0004712* and *circ_0002198* was combined, while that of *circ_0002198* was not improved (AUC = 0.82; 95% *CI*: 0.71--0.93; *P* \< 0.001). AUC: Area under the curve; circRNAs: Circular RNAs; *CI*: Confidence interval.](CMJ-131-559-g003){#F3}

Prediction of target miRNAs and mRNAs {#sec2-11}
-------------------------------------

To explore the interactions between circRNAs and miRNAs, we predicted the target miRNAs of each circRNA. Moreover, the dominant miRNAs targeted by top 10 up- and downregulated circRNAs were ranked based on mirSVR scores \[[Supplementary Table 4](#T4){ref-type="table"}\]. Of them, miR455-3p, miR876-3p, miR661, and miR323a-5p were found to be the common targets of both *circ_0004712* and *circ_0002198*. The details of the molecular interactions between these two circRNAs and above target miRNAs are depicted in [Figure 4](#F4){ref-type="fig"}. To further study how the two circRNAs regulate gene expression as ceRNAs, we also predicted the related target genes according to the miRNAs targeted by circRNAs. On basis of above prediction, a total of 29 miRNAs and 62 mRNAs were recognized as downstream targets of *circ_0004712* and *circ_0002198*. Thereafter, the circRNA-miRNA-mRNA network was constructed, which clarified the gene regulatory relationships in endometriosis \[[Figure 5](#F5){ref-type="fig"}\].

###### 

The dominant miRNAs targeted by top 10 up- and downregulated circRNAs

  circRNA               Alias              FC     *P*        Top five targeted miRNAs                                         
  --------------------- ------------------ ------ ---------- -------------------------- ------------ ----------- ------------ ------------
  Upregulation                                                                                                                
   hsa_circRNA_104195   hsa_circ_0002198   4.63   7.600E04   miR4553p                   miR8763p     miR661      miR323a5p    miR198
   hsa_circRNA_405510                      4.43   4.259E02   miR4307                    miR4506      miR5100     miR4975p     miR68323p
   hsa_circRNA_104194   hsa_circ_0004712   4.11   1.359E03   miR4553p                   let7g5p      miR8763p    miR661       miR323a5p
   hsa_circRNA_404646                      3.33   3.341E02   miR3918                    miR47265p    miR46405p   miR67625p    miR4235p
   hsa_circRNA_101501   hsa_circ_0034953   3.22   4.051E02   miR146b3p                  miR5065p     miR298      miR8735p     miR1855p
   hsa_circRNA_406483                      2.88   2.691E02   miR3353p                   miR3612      miR50025p   miR47093p    miR4933p
   hsa_circRNA_075503   hsa_circ_0075503   2.43   2.998E02   miR4673                    miR46455p    miR12265p   miR548b3p    miR3835p
   hsa_circRNA_002503   hsa_circ_0002503   2.27   4.520E02   miR67603p                  miR1182      miR68375p   miR46855p    miR3723p
   hsa_circRNA_026462   hsa_circ_0026462   2.25   3.844E02   miR223p                    miR19083p    miR1275     miR65015p    miR68293p
   hsa_circRNA_103002   hsa_circ_0004816   2.08   9.380E03   miR3305p                   miR449b5p    miR449a     miR1945p     miR34c5p
  Downregulation                                                                                                              
   hsa_circRNA_001062   hsa_circ_0001062   9.86   1.029E04   miR4307                    miR47533p    miR68093p   miR68733p    miR607
   hsa_circRNA_004183   hsa_circ_0004183   4.35   2.551E02   miR71625p                  miR68753p    miR516b3p   miR516a3p    miR46873p
   hsa_circRNA_083996   hsa_circ_0083996   3.64   3.337E03   miR581                     miR71613p    miR6134     miR78473p    miR6780b5p
   hsa_circRNA_092547   hsa_circ_0001445   3.60   3.803E04   miR67403p                  miR47985p    miR507      miR12855p    miR36645p
   hsa_circRNA_406544                      3.42   1.569E03   miR12855p                  miR3353p     miR173p     miR4422      miR6273p
   hsa_circRNA_001050   hsa_circ_0001050   3.27   1.657E03   miR36535p                  miR67585p    miR4325     miR44823p    miR6535p
   hsa_circRNA_059914   hsa_circ_0059914   3.09   1.388E02   miR3775p                   miR6086      miR47563p   miR103b      miR7673p
   hsa_circRNA_101231   hsa_circ_0000467   3.08   2.611E02   miR1535p                   miR3825p     miR520g3p   miR549a      miR520h
   hsa_circRNA_002082   hsa_circ_0002082   2.85   3.809E03   miR5125p                   miR4773      miR3611     miR47423p    miR68873p
   hsa_circRNA_405210                      2.83   3.729E03   miR68333p                  miR4659a3p   miR68093p   miR4659b3p   miR47685p

circRNAs: Circular RNAs; FC: Fold change.

![The molecular interactions between the two circRNAs and their dominant target miRNAs. The common and dominant target miRNAs of both *circ_0004712* and *circ_0002198* were miR455-3p, miR876-3p, miR661 and miR323a-5p, respectively. circRNAs: Circular RNAs.](CMJ-131-559-g004){#F4}

![The circRNA-miRNA-mRNA network. The two identified circRNAs are denoted by yellow circle nodes. The red circle nodes represent target miRNAs, and blue circle nodes are target mRNAs. circRNAs: Circular RNAs.](CMJ-131-559-g005){#F5}

Enrichment analysis of circular RNA-targeted genes {#sec2-12}
--------------------------------------------------

GO and KEGG analysis was applied to enrich the function of circRNA-targeted genes \[[Figure 6](#F6){ref-type="fig"}\]. The data indicated that the target genes of these circRNAs were mainly involved in the biological processes of creatine metabolic process, glutamine family amino acid metabolic process, and negative regulation of striated muscle cell \[[Figure 6a](#F6){ref-type="fig"}\]. The main cell component which target genes participated in were mitochondrial inner membrane, organelle inner membrane, and mitochondrion, respectively \[[Figure 6a](#F6){ref-type="fig"}\]. With regard to the molecular function, the circRNA-targeted genes play a role in phosphotransferase activity, SNAP receptor activity, and carboxylic ester hydrolase activity \[[Figure 6a](#F6){ref-type="fig"}\]. In addition, KEGG analysis revealed that target genes might participate in arginine/proline metabolism and cytokine--cytokine receptor interaction \[[Figure 6b](#F6){ref-type="fig"}\].

![GO and KEGG analysis for the circRNA-targeted mRNAs. (a) GO enrichment for the target mRNAs, including biological processes, cell component, and molecular function. (b) Annotated pathways for the target mRNAs. GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; circRNAs: Circular RNAs.](CMJ-131-559-g006){#F6}

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

In our study, we identified 88 differentially expressed circRNAs, 11 upregulated and 77 downregulated, in eutopic endometrium of patients with endometriosis compared with those in normal endometrium. Two of four upregulated circRNAs were confirmed by qPCR following a microarray screening. The two circRNAs, *circ_0004712* and *circ_0002198*, identified in the present study have not been reported in other diseases. However, we found that the increased level of *circ_0004712* and *circ_0002198* can help identify the patients with endometriosis.

To explore the role of circRNAs in endometriosis, we first performed prediction of target miRNAs for circRNAs. In the rank of top 5 target miRNAs, it was found that *circ_0004712* and *circ_0002198* act together to target miR455-3p, miR876-3p, miR661, and miR323a-5p, which have not been reported in endometriosis yet. Nevertheless, in preeclampsia patients, miR455-3p was significantly downregulated and was linked to the suppression of hypoxia signaling.\[[@ref21]\] In atherosclerosis, miR876 can induce endothelial cell apoptosis.\[[@ref22]\] Moreover, miR-661 was able to activate *p53* to inhibit cell cycle progression.\[[@ref23]\] As regards the miR-323a-5p, in patients with refractory epilepsy caused by focal cortical dysplasia, its elevated level was positively correlated with the duration of epilepsy, seizure frequency, and poor prognosis.\[[@ref24]\]

Subsequently, we also predicted the related target genes according to the miRNAs targeted by circRNAs. On basis of above prediction, a total of 29 miRNAs and 62 mRNAs were recognized as downstream targets of *circ_0004712* and *circ_0002198*. Among them, 4 targeted miRNAs and 2 mRNAs have been reported to be associated with endometriosis. For example, miR-503, repressed in endometriosis, induces apoptosis and cell cycle arrest and inhibits cell proliferation, angiogenesis, and contractility of ovarian endometriotic stromal cells.\[[@ref25]\] miR-196a, overexpressed in eutopic endometrium, activates the MEK/ERK signal and represses the progesterone receptor and decidualization from women with endometriosis.\[[@ref26]\] miR-196b, downregulated in endometriotic stromal cells, inhibits proliferation and induces apoptosis by targeting *c-myc* and *Bcl-2* expression.\[[@ref27]\] Hypoxia-coordinated AUF1/miR-148a was reported to destabilize DNA methyltransferase 1 mRNA during the pathogenesis of endometriosis.\[[@ref28]\] Besides, *TNFRSF6B* (*NM_003823*) and *PGC-1α* (*NM_002630*) have been found to participate in pathogenesis of endometriosis. For instance, decoy receptor 3 (*DcR3*)/*TNFRSF6B*, a pleiotropic immunomodulator regulated by estrogen, promotes cell adhesion and enhances endometriosis development by activating focal adhesion kinase (FAK).\[[@ref29]\] *PGC-1α*, highly expressed in ovarian endometrioma, promotes local estrogen biosynthesis by stimulating aromatase expression and activity.\[[@ref30]\]

Finally, the circRNA/miRNA/mRNA network was constructed. Functional analyses and prediction of the target genes of circRNAs were carried out in eutopic and control endometrium for the first time. The two identified circRNAs were predicted to mediate arginine and proline metabolism via *CKMT1A* and *CKMT1B*. Both genes are effective modulators of ATP synthase-coupled respiration and belongs to mitochondrial creatine kinases (MtCK), which were found to be implicated in several tumors with poor prognosis.\[[@ref31][@ref32][@ref33][@ref34]\] Overexpressed MtCK may be part of a metabolic adaptation of cancer cells and could sustain high energy turnover, but would be also protective against stress situations like hypoxia and possibly protect cells from apoptosis.\[[@ref35]\] Although endometriosis is a benign disease, it exhibits malignant-like biological behaviors, including adhesion, aggression, and angiogenesis. Consequently, we speculated that *CKMT1A*- and *CKMT1B*-mediated metabolic pathways are involved in endometriosis progression. In addition, cytokine--cytokine receptor interaction signaling pathways were predicted to have strong relationships with the target genes, such as *CCL23* (*ENST00000591423*), *CCR10* (*NM_016602*), and *TNFRSF6B (NM_003823)*. *CCL23* has been reported to enhance endothelial cell migration, invasion, adhesion, and angiogenesis,\[[@ref36][@ref37]\] which were also the pathophysiologic processes involved in endometriosis. *CCR10* and its receptors regulated tissue-specific migration, maintenance, and functions of immune cells. Increasing evidence also found that *CCR10*/ligands were frequently exploited by epithelium-originated cancer cells for their survival, proliferation, and evasion from immune surveillance.\[[@ref38]\] Moreover, the evidence revealed that *TNFRSF6B* stimulated endometriosis development by activating FAK.\[[@ref29]\]

The findings highlight the relationship between circRNAs and ovarian endometriosis, which will provide a novel biomarker for screening ovarian endometriosis and help explore the role of circRNAs in the activation of endometriosis. However, this study had several limitations. First, the sample size was small and all cases were revised AFS Stage III--IV; thus, further validation involving in larger cohorts of patients with early stages of this disease is warranted. Second, noninvasive biomarkers are more likely to evaluate the diagnostic value of circRNA in clinical applications. Further studies will be needed to assess the level of circRNA in peripheral blood or menstrual blood samples. Third, the molecular mechanism and function of the present circRNAs should be tested by associated experiments in the future.

Overall, we revealed for the first time, the circRNA expression patterns and an associated circRNA-miRNA-mRNA network between women with and without endometriosis. *circ_0004712* and *circ_0002198* were confirmed to be novel biomarkers in discriminating endometriosis from controls. Our findings lay the foundation for in-depth mechanistic studies on endometriosis, which can strengthen the reliability of the two identified circRNAs as diagnostic and therapeutic targets.

*Supplementary information is linked to the online version of the paper on the Chinese Medical Journal website*.
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